SUBSCRIBE
SUBSCRIBE
News   Drug Development

Chiron Corporation Announces Initiation Of Phase 1 Trial For CHIR-265 In Melanoma

April 11, 2006 | 
1 min read

EMERYVILLE, Calif.--(BUSINESS WIRE)--April 11, 2006--Chiron Corporation (NASDAQ:CHIR - News) today announced the initiation of a Phase 1 clinical trial of CHIR-265, a selective Raf kinase inhibitor, in patients with melanoma.

Clinical research Phase I
MORE ON THIS TOPIC
A white blood cell charging an ADC/
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong